These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 22435944

  • 21. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 22. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Gumprecht J, Gosho M, Budinski D, Hounslow N.
    Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
    [Abstract] [Full Text] [Related]

  • 23. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, TNT (Treating to New Targets) Investigators.
    J Am Coll Cardiol; 2008 Apr 15; 51(15):1448-54. PubMed ID: 18402899
    [Abstract] [Full Text] [Related]

  • 24. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators.
    Lancet; 2008 Apr 15; 364(9435):685-96. PubMed ID: 15325833
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
    Swindle JP, Potash J, Kulakodlu M, Kuznik A, Buikema A.
    Am J Geriatr Pharmacother; 2011 Dec 15; 9(6):471-82. PubMed ID: 22019005
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.
    Indian Heart J; 2008 Dec 15; 60(3):215-22. PubMed ID: 19240310
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, Cressman M.
    Am Heart J; 2004 Jul 15; 148(1):e4. PubMed ID: 15215813
    [Abstract] [Full Text] [Related]

  • 30. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
    Koren MJ, Hunninghake DB, ALLIANCE Investigators.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1772-9. PubMed ID: 15519006
    [Abstract] [Full Text] [Related]

  • 31. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E.
    J Am Coll Cardiol; 2008 Sep 09; 52(11):914-20. PubMed ID: 18772061
    [Abstract] [Full Text] [Related]

  • 32. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR, Crouse JR, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB, Simvastatin Atorvastatin HDL Study Group.
    Curr Med Res Opin; 2001 Sep 09; 17(1):43-50. PubMed ID: 11464446
    [Abstract] [Full Text] [Related]

  • 33. Differences between statins on clinical endpoints: a population-based cohort study.
    Dieleman JP, van Wyk JT, van Wijk MA, van Herpen G, Straus SM, Dunselman H, Sturkenboom MC.
    Curr Med Res Opin; 2005 Sep 09; 21(9):1461-8. PubMed ID: 16197665
    [Abstract] [Full Text] [Related]

  • 34. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators.
    N Engl J Med; 2005 Jan 06; 352(1):20-8. PubMed ID: 15635109
    [Abstract] [Full Text] [Related]

  • 35. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.
    Clin Ther; 2011 Dec 06; 33(12):1904-13. PubMed ID: 22118894
    [Abstract] [Full Text] [Related]

  • 36. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
    Neil HA, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, Livingstone SJ, Fuller JH, Hitman GA, CARDS Study Investigators.
    Diabetes Care; 2006 Nov 06; 29(11):2378-84. PubMed ID: 17065671
    [Abstract] [Full Text] [Related]

  • 37. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Chaturvedi S, Zivin J, Breazna A, Amarenco P, Callahan A, Goldstein LB, Hennerici M, Sillesen H, Rudolph A, Welch MA, SPARCL Investigators.
    Neurology; 2009 Feb 24; 72(8):688-94. PubMed ID: 18768917
    [Abstract] [Full Text] [Related]

  • 38. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial.
    Durazzo AE, Machado FS, Ikeoka DT, De Bernoche C, Monachini MC, Puech-Leão P, Caramelli B.
    J Vasc Surg; 2004 May 24; 39(5):967-75; discussion 975-6. PubMed ID: 15111846
    [Abstract] [Full Text] [Related]

  • 39. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH.
    Curr Med Res Opin; 2005 Nov 24; 21(11):1865-74. PubMed ID: 16307708
    [Abstract] [Full Text] [Related]

  • 40. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP.
    Expert Opin Pharmacother; 2008 Apr 24; 9(5):669-76. PubMed ID: 18345946
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.